Ironjustice 2010-06-07 18:48:13
Increased iron decreases .. erythropoietin .. and coincidentally iron
chelation extends life by five times in these patients.
Sooo .. giving credence to the iron … ALREADY .. being .. there and
CAUSING the problems as opposed to being .. secondary / caused BY
Future Oncol. 2007 Aug;3(4):397-403. Links
Erythropoiesis-stimulating agents versus RBC transfusion in MDS:
comparison of long-term outcomes.Mundle SD.
OrthoBiotech Clinical Affairs LLC, Bridgewater, NJ, USA and, Rush
University Medical Center, 743 Knoch Knolls Road, Naperville, IL
60565, USA. email@example.com.
Impaired erythropoiesis and refractory anemia are clinical hallmarks
of the myelodysplastic syndromes (MDS). As the disease evolves, a
steady decline in hemoglobin in these disorders invariably results in
dependence on packed red blood cell (PRBC) transfusion. Such chronic
transfusion dependence has been associated with iron overload causing
cardio-hepatic toxicity and alloimmunization, and can result in
reduced survival in these patients. The use of hematopoietic growth
factors, particularly erythropoiesis-stimulating agents (ESAs), has
been reported to reduce the need for PRBC transfusion, raise
hemoglobin and improve quality of life, at least in patients
responding to such a therapy. Importantly, the clinical benefits of
ESA are well balanced, with an apparently favorable safety profile in
MDS, thus providing an eminent therapeutic option to delay or avoid
transfusion dependence in these patients. The present report provides
a detailed comparative profile of long-term PRBC transfusions and the
balance of clinical benefits versus risks associated with ESA therapy
PMID: 17661714 [PubMed – in process]
Who loves ya.
Jesus Was A Vegetarian!
Man Is A Herbivore!
DEAD PEOPLE WALKING